QSAR Studies and Scaffold Optimization of Predicted Novel ACC 2 Inhibitors to treat Metabolic Syndrome

CONCLUSION: The compounds designed in the present study have tremendous potential to yield orally active ACC 2 inhibitors to treat metabolic syndrome.PMID:37680153 | DOI:10.2174/1570163820666230901144003

Source: Current Drug Discovery Technologies - September 8, 2023 Category: Drugs & Pharmacology Authors: Kirtika Madan Sarvesh Paliwal Swapnil Sharma Seema Kesar Neha Chauhan Mansi Madan Source Type: research